Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for hydroxychloroquine
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on hydroxychloroquine or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on hydroxychloroquine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial 29125901 2018 08 29 2151-4658 70 9 2018 Sep Arthritis care & research Arthritis Care Res (Hoboken) Efficacy of Hydroxychloroquine in Hand Osteoarthritis: A Randomized, Double-Blind, Placebo-Controlled Trial. 1320-1325 10.1002/acr.23471 To determine the symptom-modifying effect of hydroxychloroquine (HCQ) in hand osteoarthritis (OA). In this randomized, double-blind, multicenter trial
Hydroxychloroquine Top results for hydroxychloroquine - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box (...) and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for hydroxychloroquine The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical
A case of exogenous ochronosis associated with hydroxychloroquine 30071940 2018 11 14 2147-9720 5 3 2018 Sep European journal of rheumatology Eur J Rheumatol A case of exogenous ochronosis associated with hydroxychloroquine. 206-208 10.5152/eurjrheum.2018.17190 Exogenous ochronosis is characterized by hyperpigmented skin lesions that arise in association with local suppression of homogentisic acid oxidase enzyme. Although it generally develops in association with topical application of chemical (...) agents, it can occasionally develop in association with antimalarial drugs. Here we present the case of a patient with rheumatoid arthritis who developed hyperpigmentation on the face and neck regions during hydroxychloroquine treatment. Hydroxychloroquine is being widely used in rheumatology practice, and cutaneous hyperpigmentation may develop as an adverse effect. In the present case, we emphasize the potential underlying mechanisms through which it may cause cutaneous hyperpigmentation
Hydroxychloroquine Effectiveness in Reducing Symptoms of Hand Osteoarthritis: A Randomized Trial. Background: Synovitis is believed to play a role in producing symptoms in persons with hand osteoarthritis, but data on slow-acting anti-inflammatory treatments are sparse. Objective: To determine the effectiveness of hydroxychloroquine versus placebo as an analgesic treatment of hand osteoarthritis. Design: Randomized, double-blind, placebo-controlled clinical trial with 12-month follow-up (...) . (ISRCTN registry number: ISRCTN91859104). Setting: 13 primary and secondary care centers in England. Participants: Of 316 patients screened, 248 participants (82% women; mean age, 62.7 years) with symptomatic (pain ≥4 on a 0- to 10-point visual analogue scale) and radiographic hand osteoarthritis were randomly assigned and 210 (84.7%) completed the 6-month primary end point. Intervention: Hydroxychloroquine (200 to 400 mg) or placebo (1:1) for 12 months with ongoing usual care. Measurements
Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. 28025216 2016 12 27 2017 03 31 2055-6845 3 2 2017 Apr 01 European heart journal. Cardiovascular pharmacotherapy Eur Heart J Cardiovasc Pharmacother Hydroxychloroquine for the prevention of recurrent cardiovascular events in myocardial infarction patients: rationale and design of the OXI trial. 92-97 10.1093/ehjcvp/pvw035 Inflammation of the arterial (...) wall plays a central role in the pathogenesis of atherosclerosis. Among patients with rheumatic diseases, anti-rheumatic medication reduces the incidence of cardiovascular (CV) diseases, but only few studies have addressed their cardioprotective effects on patients with no rheumatic diseases. Hydroxychloroquine (HCQ) is an anti-rheumatic drug commonly used in the treatment of rheumatoid arthritis and systemic lupus erythematosus. In addition to its anti-inflammatory properties, HCQ reduces
Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. 27747530 2016 10 17 2017 02 20 2198-6576 2 2 2015 Dec Rheumatology and therapy Rheumatol Ther Pharmacokinetics and Bioequivalence Study of Hydroxychloroquine Sulfate Tablets in Chinese Healthy Volunteers by LC-MS/MS. 183-195 Hydroxychloroquine (HCQ), 4-aminoquinoline, is an antimalarial drug and has become a basic therapy for rheumatic disease treatment. It can stabilize (...) to acquire regulatory approval for the test formulation. This study was conducted with a randomized, single-dose, two-period, and crossover design. The male subjects were randomly assigned to two groups at a 1:1 ratio to receive 0.2 g hydroxychloroquine sulfate tablets (0.1 g/piece) of the two formulations after a 3-month washout period then administered the alternate formulation. Study drugs were administered after overnight fasting (over 10 h). Plasma concentrations of hydroxychloroquine were measured
Plaquenil (hydroxychloroquine sulfate) - Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, systemic lupus erythematosus, Prevention of polymorphous light eruption HAS - Medical, Economic and Public Health Assessment Division 1/11 The legally binding text is the original French version T TR RA AN NS SP PA AR RE EN NC CY Y C CO OM MM MI IT TT TE EE E Opinion 23 July 2014 PLAQUENIL 200 mg, film-coated tablet B/30 (CIP: 34009 364 (...) 414 6 0) Applicant: SANOFI-AVENTIS France INN hydroxychloroquine sulfate ATC code (2014) P01BA02 (synthetic antimalarials) Reason for the review Renewal of inclusion List concerned National Health Insurance (French Social Security Code L.162-17) Indications concerned “Long-acting symptomatic treatment of rheumatoid arthritis, Discoid lupus erythematosus, Subacute lupus erythematosus, Adjuvant or preventive treatment of relapses of systemic lupus erythematosus, Prevention of polymorphous light
Hydroxychloroquine in the Treatment of Osteoarthritis "Hydroxychloroquine in the Treatment of Osteoarthritis" by Briana Hougum < > > > > > Title Author Date of Award Summer 8-8-2015 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Annjanette Sommers, MS, PA-C Rights . Abstract Background : Osteoarthritis (OA) accounts for one of the most common causes of loss of work and disability in America. Traditional treatments are aimed at symptomatic (...) relief and maintaining functional capacity, but have not been shown to modify disease progression. Evidence for inflammatory and immune components in the development of OA lend support to expanding treatment options to potentially slow the disease and delay the need for invasive surgical intervention. Hydroxychloroquine (HCQ) is known for its use as an antimalarial and as a DMARD for rheumatoid arthritis, but has also been considered an option for treatment resistant OA. Several studies have looked
Effects of hydroxychloroquine on symptomatic improvement in primary SjÃ¶gren syndrome: the JOQUER randomized clinical trial. 25027140 2014 07 16 2014 07 28 2016 10 17 1538-3598 312 3 2014 Jul 16 JAMA JAMA Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial. 249-58 10.1001/jama.2014.7682 Primary Sjögren syndrome is a systemic autoimmune disease characterized by mouth and eye dryness, pain, and fatigue. Hydroxychloroquine (...) is the most frequently prescribed immunosuppressant for the syndrome. However, evidence regarding its efficacy is limited. To evaluate the efficacy of hydroxychloroquine for the main symptoms of primary Sjögren syndrome: dryness, pain, and fatigue. From April 2008 to May 2011, 120 patients with primary Sjögren syndrome according to American-European Consensus Group Criteria from 15 university hospitals in France were randomized in a double-blind, parallel-group, placebo-controlled trial. Participants were
Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study) 23144449 2013 10 04 2013 11 26 2014 05 12 1468-2060 72 11 2013 Nov Annals of the rheumatic diseases Ann. Rheum. Dis. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study). 1786-92 10.1136/annrheumdis-2012-202322 Hydroxychloroquine (HCQ) is an important medication for treating systemic lupus erythematosus (SLE). Its blood (...) Comparative Study Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't 2012 11 10 England Ann Rheum Dis 0372355 0003-4967 0 Antirheumatic Agents 4QWG6N8QKH Hydroxychloroquine IM Adult Antirheumatic Agents administration & dosage blood Dose-Response Relationship, Drug Double-Blind Method Drug Monitoring methods Female France Humans Hydroxychloroquine administration & dosage blood Lupus Erythematosus, Systemic drug therapy Male Middle Aged Prospective Studies
Hydroxychloroquine in decompensated, treatment-refractory noninsulin-dependent diabetes mellitus. A new job for an old drug? Hydroxychloroquine in decompensat... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1990 ) Volume: 112 , Issue: 9 , Pages: 678-681 PubMed: Available from or Find this paper at: Abstract STUDY OBJECTIVE: To evaluate the usefulness and safety of hydroxychloroquine (...) who continued the previous treatment but took either placebo tablets or hydroxychloroquine, 200 mg three times a day. The four subgroups were as follows: insulin and placebo (n = 11); insulin and hydroxychloroquine (n = 11); glibenclamide and placebo (n = 8); and glibenclamide and hydroxychloroquine (n = 8). MEASUREMENTS AND MAIN RESULTS: At 6 months, relevant and statistically significant improvement occurred in the 11 patients who received the insulin and hydroxychloroquine (glucose profile
Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. 22820788 2012 07 23 2012 07 27 2016 12 03 1538-3598 308 4 2012 Jul 25 JAMA JAMA Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. 353-61 10.1001/jama.2012.6936 Therapies to decrease immune activation might (...) be of benefit in slowing HIV disease progression. To determine whether hydroxychloroquine decreases immune activation and slows CD4 cell decline. Randomized, double-blind, placebo-controlled trial performed at 10 HIV outpatient clinics in the United Kingdom between June 2008 and February 2011. The 83 patients enrolled had asymptomatic HIV infection, were not taking antiretroviral therapy, and had CD4 cell counts greater than 400 cells/μL. Hydroxychloroquine, 400 mg, or matching placebo once daily for 48
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial 23196701 2013 11 05 2014 01 20 2015 11 19 1468-2060 72 12 2013 Dec Annals of the rheumatic diseases Ann. Rheum. Dis. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results (...) of the randomised, controlled, SWEFOT trial. 1927-33 10.1136/annrheumdis-2012-202062 To compare EuroQol 5-Dimensions (EQ-5D) utility and quality-adjusted life-years (QALYs) in patients with early, methotrexate (MTX) refractory rheumatoid arthritis (RA), randomised to addition of infliximab (IFX) or sulfasalazine and hydroxychloroquine (SSZ+HCQ). RA-patients with symptoms <1 year were enrolled between 2002 and 2005 at 15 Swedish centres. After 3-4 months of MTX monotherapy, patients with a remaining DAS28>3.2
Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases Sperber K, Hom C, Peng Chao C, Shapiro D, Ash J CRD summary This review concluded that hydroxychloroquine use in pregnant women with autoimmune diseases was not associated with increased risk of congenital defects, spontaneous (...) abortions, live births, fetal death or prematurity. This was a well-conducted review, but the limitations of the included studies acknowledged by the authors should be borne in mind when interpreting the results. Authors' objectives To compare the incidence of congenital defects, spontaneous abortions, number of live births, fetal death and pre-maturity in women with autoimmune diseases taking hydroxychloroquine (HCQ) during pregnancy. Searching MEDLINE, Current Contents Clinical Medicine, Embase Drugs
Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. 19665644 2009 08 11 2009 09 08 2015 11 19 1474-547X 374 9688 2009 Aug 08 Lancet (London, England) Lancet Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised (...) trial. 459-66 10.1016/S0140-6736(09)60944-2 New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying antirheumatic drugs (sulfasalazine and hydroxychloroquine) with addition of a tumour necrosis factor antagonist (infliximab) to methotrexate in patients with early rheumatoid arthritis. We undertook a randomised trial in 15 rheumatology units in Sweden. We enrolled patients with early rheumatoid arthritis (symptom
Hydroxychloroquine and ocular toxicity recommendations on screening The Royal College of Ophthalmologists - Hydroxychloroquine and Ocular Toxicity Recommendations on Screening – October 2009 Page 1 of 9 The Royal College of Ophthalmologists Hydroxychloroquine and Ocular Toxicity Recommendations on Screening October 2009 Scientific Department The Royal College of Ophthalmologists 17 Cornwall Terrace Regent’s Park London NW1 4QW Telephone: 020 7935 0702 Facsimile: 020 7487 4674 www.rcophth.ac.uk (...) The Royal College of Ophthalmologists - Hydroxychloroquine and Ocular Toxicity Recommendations on Screening – October 2009 Page 2 of 9 Hydroxychloroquine and Ocular Toxicity Recommendations on Screening (Replacing the Royal College of Ophthalmologists Guidelines for Screening 2004 and 1998) Background Hydroxychloroquine is a quinolone used primarily by rheumatologists for rheumatoid arthritis and systemic lupus erythematosus, and by dermatologists for cutaneous lupus. Although its mechanism of action
Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. CONTEXT: Hydroxychloroquine, a commonly used antirheumatic medication, has hypoglycemic effects and may reduce the risk of diabetes mellitus. OBJECTIVE: To determine the association between hydroxychloroquine use and the incidence of self-reported diabetes in a cohort of patients with rheumatoid arthritis. DESIGN, SETTING, AND PATIENTS: A prospective, multicenter observational study of 4905 adults with rheumatoid (...) arthritis (1808 had taken hydroxychloroquine and 3097 had never taken hydroxychloroquine) and no diagnosis or treatment for diabetes in outpatient university-based and community-based rheumatology practices with 21.5 years of follow-up (January 1983 through July 2004). MAIN OUTCOME MEASURES: Diabetes by self-report of diagnosis or hypoglycemic medication use. RESULTS: During the observation period, incident diabetes was reported by 54 patients who had taken hydroxychloroquine and by 171 patients who had
Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1. Most people who have HIV-1 and live in less-developed countries cannot afford standard combination antiretroviral therapy, and more economical approaches to treatment are therefore needed. We treated 22 patients who were infected with HIV-1 (viral load < 100000 copies/mL and CD4 count >150 cells/microL) with hydroxychloroquine (200 mg), hydroxycarbamide (hydroxyurea) (500 mg), and didanosine (125-200 mg
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy. To obtain safety data for its use in pregnancy, we did ophthalmic examinations in 21 children born to women who took these drugsduring pregnancy. Average daily maternal doses of the two drugs were 317 mg hydroxychloroquine and 332 mg chloroquine